Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study

医学 回顾性队列研究 内科学 优势比 置信区间 气胸 人口 联合疗法 肺栓塞 外科 环境卫生
作者
Murat Bektaş,Mustafa Ay,Muhammed Hamdi Uyar,Muhammed İkbal Kılıç
出处
期刊:International Immunopharmacology [Elsevier BV]
卷期号:129: 111586-111586 被引量:1
标识
DOI:10.1016/j.intimp.2024.111586
摘要

In this study, we aimed to evaluate the safety and efficacy of combination treatment of high-dose intravenous anakinra and baricitinib in patients with critically ill COVID-19. This retrospective observational study was conducted in a tertiary center with diagnosis of COVID-19 patients. Study population consisted of patients with positive polymerase chain reaction and computer tomography findings compatible with COVID-19 as well as critical illness. Data of 15 patients in combination group and 43 patients in control group were evaluated and included into the study. Overall mortality was 46.7 % (n = 7) in combination arm and 69.8 % (n = 30) in control group although it was not statistically significant (p = 0.1). Similarly, need of intubation was also lower in combination arm (46.7 %) compared to control group (69.8 %), it was not significantly different (p = 0.1). ICU admission was significantly lower in combination (46.7 %, n = 7) arm than control group (76.7 %, n = 33) (p = 0.03, Odds ratio [OR]:4.7). Development of severe infection (20 %, n = 3 vs 25 %, n = 9/36), pulmonary embolism (6.7 %, n = 1 vs 0), myocardial infarction (6.7 %, n = 1 vs 2.6 %, n = 1/38) and pneumothorax (13.3 %, n = 2 vs 2.6 %, n = 1/38) were not different between two groups (p = 0.7, p = 0.3, p = 0.5 and p = 0.2). In multivariable analysis only cHIS score was associated with high mortality (p = 0.018, OR:2.8, [95 % confidence interval: 1.2–6.6]). In survival analysis, mortality rate was significantly lower in combination arm than control group (Log-Rank:p = 0.04). Combination therapy of high-dose anakinra and baricitinib may be an adequate treatment option in patients with COVID-19 who had critical disease and has acceptable safety profile.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
酷波er应助享音采纳,获得10
刚刚
刚刚
刚刚
1秒前
宋浩然完成签到,获得积分10
1秒前
1秒前
2秒前
2秒前
美少女发布了新的文献求助10
2秒前
777发布了新的文献求助10
2秒前
Dowe完成签到,获得积分10
3秒前
3秒前
爸爸完成签到 ,获得积分10
4秒前
姗姗xl发布了新的文献求助10
4秒前
甜蜜的傲蕾完成签到,获得积分10
4秒前
5秒前
糖果完成签到,获得积分10
5秒前
Dritsw应助李长印采纳,获得10
5秒前
淡淡大山发布了新的文献求助10
6秒前
6秒前
6秒前
6秒前
77发布了新的文献求助10
6秒前
fyjlfy完成签到 ,获得积分10
6秒前
lalala发布了新的文献求助10
7秒前
yaoyh_gc发布了新的文献求助10
7秒前
7秒前
7秒前
华仔应助傅傅采纳,获得10
8秒前
小蘑菇应助twob采纳,获得10
8秒前
Luckqi6688完成签到,获得积分10
8秒前
like发布了新的文献求助10
9秒前
NexusExplorer应助niuwenyu采纳,获得10
9秒前
唐糖完成签到,获得积分10
9秒前
顺利墨镜发布了新的文献求助10
10秒前
蓝橙发布了新的文献求助10
10秒前
11秒前
碧蓝世立完成签到,获得积分10
11秒前
靓丽从筠完成签到 ,获得积分10
11秒前
Yoh1220发布了新的文献求助50
11秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970683
求助须知:如何正确求助?哪些是违规求助? 3515337
关于积分的说明 11178055
捐赠科研通 3250580
什么是DOI,文献DOI怎么找? 1795357
邀请新用户注册赠送积分活动 875790
科研通“疑难数据库(出版商)”最低求助积分说明 805166